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INTRODUCTION 
 
             Pneumonia is  major  cause  of  mortality  and  morbidity  in  both  
developing  countries  and  developed  countries.  It is next to diarrhea 
among all  acute  infectious  disease  in mortality.  It affects all age 
groups.  Pneumonia is the major cause of death in children under five 
years  and extremes of age.  Due  to  over usage  and misusage  of  oral  
and intra venous  antibiotics,  patients  are   infected  with  multidrug 
resistant pathogens. This can lead to healthcare associated pneumonia. 
         Due to lack of knowledge, lack of facilities, pneumonia most often 
misdiagnosed, under estimated  and  mistreated.  One other reason for 
poor outcome of patients is, failure to assess the severity of the disease 
and  to  treat  patient  as  outpatient  or in  hospital  setup  or  in  intensive  
care  unit. Pneumonia is more common in immune compromised like 
Diabetes, HIV and patient with chronic lung disease.  
 
 
 
 
 
 
  
 
 
 
AIM AND OBJECTIVES 
The study focuses on Clinical, Radiological and Bacteriological 
aspects of patients admitted in CMCH with Pneumonia. 
 
 
OBJECTIVES: 
The objectives of the study are as follows, 
• To know the prevalence of causative microorganism of 
COMMUNITY ACQUIRED PNEUMONIA in 
Coimbatore region. 
• Clinical presentation of patients. 
• Radiological profile of the above patients. 
 
 
 
 
 
 
 
 
  
 
 
REVIEW OF THE LITERATURE 
 
DEFINITION 
Pneumonia is defined as infection of lung parenchyma, it may be 
due to infectious or non infectious.  
 
EPIDEMIOLOGY 
Pneumonia is sixth leading cause of death in United States. The 
death rate per 100,000 patients was 21.8. In 2009, according to the 
centers for disease control and prevention, 1.1 million people were 
hospitalized, which among more than 50,000 were died from pneumonia
1
.  
In spite of having total number of deaths due to lower respiratory tract 
infections available, there is no systemic study conducted on incidence of 
pneumonia in India. According to World Health Organization, in India 
mortality due to infectious disease is caused by lower respiratory tract 
infections is around 20%.  
 
 
 
 
 
  
 
 
ETIOLOGY  
Etiology of CAP may be infective or non infective causes
2
. 
I. Infective causes: 
Bacteriological causes : 
• Staphylococcal pneumonia 
• Pneumococcal pneumonia 
• Pseudomonas pneumonia 
• Klebsiella pneumonia 
• Haemophilus influenza pneumonia 
• Escherichia pneumonia 
• Chlamydia pneumonia 
• Morexella catarrhalis pneumonia 
• Mycoplasma  pneumonia 
• Legionella pneumonia 
Viral causes : 
• Measles virus 
• Influenza, cytomegalo virus 
• Hanta virus 
• Respiratory synctial 
• Corona virus 
• Metapneumo virus 
 
Other agents like coccidiodes, histoplasma, parasitic pneumonia 
and blastomycoces produces pneumonia. 
 
  
 
 
2. Non infective  
Non Infective causes like Radiation Pneumonia and lipid physical 
pneumonia
3
.The most common causes of CAP depends on the situations 
where the infection occurs, as shown below
4
, 
 
Table : Causes of CAP 
 
 
 
  
 
 
According to risk factor and epidemiologic condition, the pathogen 
aetiological agent may vary in CAP 
5
. Which are  
 
Condition Pathogens commonly encountered 
Age more than 65years Streptococcus pneumonia 
Co morbidity like 
cardiovascular disease,  
COPD,  diabetes mellitus, 
neurological disease , recent 
viral infection, chronic renal 
or liver failure 
Staphylococcus aureus 
Gram negative enteric bacilli 
Streptococcus pneumoniae 
Haemophilus influnzae 
 
Aspiration 
 
Oral anaerobes,  Gram negative enteric 
bacilli 
Exposure to bird or bat 
droppings 
Histoplasma capsulatum 
 
Rabits exposure Francisella tularensis 
HIV infection (late) 
 
Streptococcus pneumonia 
M.tuberculosis 
Haemophilus influnzae 
Cryptococcus 
Pneumocystis jirovecii, Aspergillus 
Histoplasma, P.aeruginosa  
Atypical mycobacteria 
HIV infection (early) Streptococcus pneumonia 
M.tuberculosis 
Haemophilus influnzae 
Travel to or residence in 
southwestern united states 
Hanta virus 
 Coccidiodes species 
Community  where Influenza 
is active  
 
Staphylococcus aureus 
Streptococcus pneumoniae 
Haemophilus influnzae 
Influenza 
  
 
 
Structural lung diseases like 
Bronchiectasis 
 
Staphylococcus aureus 
P.aeruginosa  
Burkholderia cepacia 
Endobronchial Obstruction 
 
Staphylococcus aureus 
Streptococcus pneumoniae 
Haemophilus influnzae 
Anaerobes 
Alcoholism 
 
Streptococcus pneumonia 
M.tuberculosis 
Acinetobacter species 
Klebsiella pneumonia 
Oral anaerobes 
Patients in Institutions 
 
Staphylococcus aureus 
Gram negative enteric bacilli 
Streptococcus pneumonia 
Anaerobic bacteria in elderly non 
ambulatory patients 
Smoking and/or COPD 
 
Streptococcus pneumoniae 
Haemophilus influnzae 
Legionella species 
P.aeruginosa  
Chlamydophilis pneumonia 
Moraxella catarrhalis 
Lung abscess 
 
Staphylococcus aureus 
M.tuberculosis 
Community acquired MRSA 
Atypical mycobacteria 
Endemic fungal 
Oral anaerobes 
Exposure to birds 
 
Chlamydophilia psittaci  
Avian influenza if poultry 
Exposure to parturient cats or 
farm animals 
Coxiella burnetti 
 
  
 
 
Cruise or hotel stay in last 2 
weeks 
Legionella species 
 
Travel to or residence in 
south east and east asia 
Severe acute respiratory syndrome 
Avian influenza 
Burkholderia pseudomallei 
Post tussivative vomiting or 
whooping cough for 12 weeks 
Bordetella pertussis 
 
Drug use as injection 
 
Staphylococcus aureus 
M.tuberculosis 
Streptococcus pneumonia 
Anaerobes 
Hospital Admission 
 Within 3 to 4 weeks 
Within one year 
Gram negative enteric bacilli 
Streptococcus pneumonia 
 
Bioterrorism context 
 
Francisella tularensis, Yersinia pestis, 
Bacillus anthracis 
Treated with antibiotics like 
penicillin and others 
Resistant micro organisms 
Streptococcus pneumonia 
 
Classification of Pneumonia: 
       Based on different studies, there are different types of classification 
as described below
6
. 
1. Anatomical classification : 
a) Bronchopneumonia 
b)  Lobar pneumonia 
c) Segmental Pneumonia 
d) Sub segmental Pneumonia 
 
  
 
 
2. Microbiologist’s classification 
a) Bacterial 
b) Bacteria like and Rickettsia like pneumonia 
c) Viral 
d) Fungal 
e)  Chemical Pneumonia 
f)  Parasitic Pneumonia 
g)  Physical pneumonia – ionizing pneumonia 
 
3.Empiricist’s classification: 
a) Hospital Acquired Pneumonia 
b) Community Acquired Pneumonia 
c) Immuno compromised pneumonia – AIDS related 
d) Aspiration pneumonia. 
 
4. Behaviorist’s classification: 
a) Difficult pneumonia 
b) Easy pneumonia 
Causative organism based classification of pneumonia is more 
widely used when compared to anatomical based classification of 
pneumonia. There are some conditions when lesion in lung is diagnosed 
  
 
 
as pneumonia  but it fails to responds to treatment or rather it responds 
very late, then we name it as Non resolving Pneumonia
7
.   
Different physicians around the globe defined the non resolving 
pneumonia on basis of their own opinion, for example on basis of 
radiological infiltration not resolving, due time course of ten days with 
antibiotic therapy
8
. There are also some conditions which become 
challenge to Physician, whether its delaying resolution due to host factor 
or diagnosis should be reconsidered, such as systemic immunological 
disease and congestive cardiac failure. Conditions like pulmonary 
embolism, pulmonary alveolar proteinosis, sarcoidosis, hypersensitive 
pneumonitis, systemic necrotizing vasculitis, Wegner’s granulomatosis 
and drug induced pneumonitis mimic like non- resolving pneumonia
9
. 
CAP defined as less than one week cough with or without 
expectoration, shortness of breath, pleuritic pain with at least one 
systemic feature such as chills and rigor, temperature more than 37.7 
degree celcius or malaise and new focal chest sign like Bronchial breath 
sound or crackles and having no other explanation for the illness and 
patient is not in the hospital or other health care system and patient 
acquired infection in community setting
10
. 
With available chest radiography in the hospital CAP is defined 
with above said symptom and chest X ray finding of patchy or lobar 
consolidation. Before diagnosing Pneumonia we should rule out some 
  
 
 
conditions such as pulmonary edema, pulmonary infarction and acute 
respiratory distress syndrome
11
. 
 
PATHOGENESIS: 
Lung Anatomy: 
        Lung is a spongy structure which helps in purifying blood. There 
are three lobes in the right lung and two lobes in the left lung. Left lung is 
smaller than right lung. Lingual in the left lung is equivalent to middle 
lobe of the right lung. Right Main bronchus is more vertical than the left 
one. Because of this reason, aspirated materials such as vomit, blood or 
any other foreign body mostly enters right lung rather than the left lung
12
.  
Both bronchi gives rise to bronchioles. Bronchioles are differentiated 
from bronchi by lack of submucosal glands and lack of cartilage. 
Bronchioles gives rise to terminal bronchioles with diameter less than 
2mm. distally to terminal bronchioles called as acinus, which are 
spherical approximately with 7mm diameter.   Terminal bronchioles 
leadsto respiratory bronchioles which proceeds to alveolar ducts which 
branches to alveolar sacs
13
. Alveolar sacs are blind ends where gas 
exchange takes place. 
 
 
 
  
 
 
Alveolar walls under microscopy consists of, from blood to air, 
1. The interwining network of anastomosing capillaries by the 
Capillary endothelium. 
2. A basement membrane and surrounding interstitial tissue, which 
separates epithelial cells of alveolar lining from endothelial cells,   
3. Alveolar epithelium, two cell types, continuous in nature. 
a. 95% of surface covered by type I pneumocytes, which are 
flattened and plate like. 
b. Type II pneumocytes, which are rounded. 
  There are two major reasons why type II pneumocytes are more 
important than type I pneumocytes
14
. They are  
i. After type I cell destruction, Type II cells are those, which 
helps in repair of destructed alveolar epithelium .   
ii. Type II pneumocytes are sources of pulmonary surfactant, in 
which under electron microscope contains osmophilic 
lamellar bodies. 
4.  Alveolar Macrophages. Which may present free in alveolar spaces 
or attached loosely to epithelial cells. Some Phagocytosed materials 
and carbon particles are filled in alveolar macrophages. 
 
  
 
 
The walls of alveoli are not solid in nature but contains many 
number of Pores of Kohn. Between adjacent alveoli, these pores allows 
bacteria and exudates
15
. 
       Our human body consist of numerous amount of microbial 
species from oral cavity to excretory passage. More than 200 microbial 
species are present in upper respiratory tract, with both aerobic and non 
aerobic microbes. Generally there is a belief that lower respiratory tract 
below larynx level is usually sterile
16
. Clinically, severity of respiratory 
tract infection may vary in ranges, from simple illness like common cold 
to severe illness like pneumonia. 
By inhalation and contaminated micro droplets, micro-organisms 
enters the lower respiratory tract. Increased number of aspiration of 
nasopharyngeal flora and long time exposure of contaminated air makes 
lung parenchyma vulnerable to invasion of micro organisms. Particles 
which are less than 5 micro meter in diameter reach the alveoli very 
easily. Particles of size larger than 10 micro meter get trapped in nasal 
secretions
17
. Particles of size more than 100 micrometer are precipitated 
easily and are not easily inhaled. 
In upright position the inhaled micro organism deposit is higher in 
the lower lobe, since lower lobe has plenty of ventilation in upright 
position. Comparing to other type of pneumonia, inhalation pneumonia is 
very easily affected and more often are due to micro organisms which are 
  
 
 
size less than 5 micrometer, high inoculums carrier, in transit time it 
survive long enough, remain suspend in the air, can travel long in air, 
defeat local host defense mechanism easily.  
           There are several ways through which infection spreads such as 
aerosol inhalation, aspiration, oropharyngeal secretion, haematogenous 
spread and reactivation of latent micro organisms
18
.  
Defence Mechanism  
Lung maintains its bacteria free position by immune respiratory 
defence mechanism and non immune respiratory defence mechanism, 
which works very effectively at different levels of lungs. 
    The respiratory defence mechanisms are located in different levels 
which are as follows. 
a. Nasopharynx acts as defence mechanism by presence of nasal 
hair and turbinates, IgA secretions and mucocilliary apparatus. 
b. Trachea and bronchi acts as defence mechanism by cough, 
epiglottic reflex, immunoglobin ( IgG, IgM and IaA) secretions 
and mucocilliary apparatus. 
c. Terminal airways and alveoli acts as defence mechanism by 
pulmonary lymphatics, cell mediated immunity, alveolar 
macrophages, cytokines( interleukin – 1, tumor necrosis factor), 
alveolar lining fluid (surfactant, complement, Ig, fibronectin) 
and polymorphonuclear leukocytes. 
  
 
 
 
   Sometimes the above said defence mechanisms may get impaired, 
which leads to failure to defence the microbes entering in to lungs and 
cause damage causing infection. They are as follows, 
o Depressed glottis reflex and cough 
This may leads to the aspiration of gastric content in old age 
patients and patients with thoracoabdominal surgery, COPD and 
neuromuscular disease. 
 
2. Alteration of normal oropharyngeal flora  
Microorganism colonization is oropharynx is prevented by 
presence of normal flora, complement and local immune globulins mainly 
immunoglobulin A. some chronic systemic disorders, malnutrition, 
diabetes and alcoholism reduces salivary fibronectin levels and increases 
gram negative bacilli colonization. Resistant gram negative bacilli 
colonization may be due to suppression of the normal oral flora due to 
over usage and misusage of inappropriate antibiotics. 
 
3. Mucociliary apparatus mechanism impairment  
Physical properties of mucus and effective ciliary motion causes 
effective mucociliary clearance. Airway surface fluid are produced by 
surface epithelial globlet cells and sub mucosal glands. This fluid consists 
  
 
 
of lower layer of non gel liquid and upper gel like mucin. The cilia 
pushes gel towards mouth. Exposure to hot or cold air, chronic cigarette 
smoking, some harmful gases and viral respiratory infections causes 
damage to mucous from larynx up to the terminal bronchioles. 
 
4. Altered Consciousness  
During deep sleep approximately 50% of oropharyngeal secretions 
are aspirated by normal healthy individual. Oropharyngeal contents, 
which contains over 100 million bacteria per milliliter of secretion may 
often aspirated in some conditions like alcoholism, seizure, coma, CNS 
depressant drugs over dosage and cerebro vascular accidents.  
5. Immune dysfunction : 
Infections caused by pathogenic microorganisms are fought with 
the help of immune system including respiratory tract. recognition of 
antigens by B and T lymphocytes are important for immune response
19
.  
Such responses are regulated by macrophages, mast cells, neutroplils, 
pulmonary dendritic cells and eosinophils. Immunosuppressive therapies, 
disorders of lymphocytes, granulocytes and congenital/ acquired immune 
deficiencies may predispose to infection like pneumonia. 
 
 
 
  
 
 
6. Dysfunction of alveolar macrophage : 
Alveolar macrophages are very highly effective phagocytic cells 
which are capable of scavenging very wide spectrum of the particulate 
bodies. Lysosomal system breaks micro organism, substance escapes this 
will be isolated in secondary lysosomes and stay there for life span of 
macrophages. Generation of reactive oxygen species, toll like receptor 
protein and nitric oxide formation other important macrophages. By 
causing impairment of alveolar macrophages,chronic anaemia, 
hypoxemia, prolonged starvation, respiratory viral infection and chronic 
cigarette smoking helps in the occurrence of pneumonia
20
. 
CAP mainly caused by bacteria or virus. Most of the time viral 
infection follows to bacterial infection. Invasion of bacteria to lung 
parenchyma causes the filling of alveoli with inflammatory exudates 
which causes Consolidation or solidification of lung tissue.  There are 
different factors which determines the form of pneumonia such as host 
reaction, specific etiologic agent and extend of the involvement
21
. 
On basis of anatomic distribution, bacterial pneumonia divided into 
two gross patterns like Lobar pneumonia and lobular broncho pneumonia. 
Lobar pneumonia is acute bacterial infection causing fibrinosuppurative 
consolidation of a entire lobe or the large portion of a single lobe. 
Broncho pneumonia causes patchy consolidation of lung. 
  
 
 
   Many a times the anatomical pattern of classification 
overlaps and its really difficult to differentiate what kind of pneumonia it 
is. For example use of antibiotic restricts the progression of disease and 
express as subtotal infection or sometimes diffuse patchy consolidation 
expresses as lobar pattern. Moreover, an organism can cause lobar 
pneumonia in one patient and can cause broncho pneumonia in other 
patient
22
. From clinical stand point is very important to determine the 
extent of the disease and identify the causative organism. 
The inflammatory response in Lobar pneumonia is classified in four 
stages as follows. 
1. Congestion 
2. Red hepatization 
3. Grey hepatization 
4. Resolution 
   In recent days use of antibiotics halts or slows down the progression of 
disease. 
1. Congestion  
          In Initial stage of consolidation, lung is red, boggy and heavy, 
which is characterized by intraalveolar fliud with neutrophils, vascular 
engorgement and presence of plenty of bacteria's. 
 
 
  
 
 
o Red hepatization 
        The red hepatization stage characterized by alveolar space filled 
with massive exudates with fibrin, neutrophils and red cells. The lobe 
appears airless, firm, red and liver like consistency. So the stage is termed 
as Red Hepatization. 
o Grey Hepatisation : 
        The red cell disintegrate progressively and fibrinoeuppurative 
exducate persistence makes lung surface dry and gives gross appearance 
of grayish brown. This stage is Gray Hepatization. 
o Resolution : 
    In final Resolution stage, fibrins, bacteria and neutrophils get cleared 
and in alveolar space macrophages reappears, as the inflammatory 
response. 
Pneumonia Caused by Different Microbes : 
Infection caused by different microbes are explained below
23
, 
 
Streptococcus Pneumoniae 
The most common and most important cause of CAP is 
Streptococcus Pneumoniae. The very most important step in diagnosing 
acute pneumonia is Gram stained sputum examination. It is more specific 
to Isolate pneumococci from blood culture and in early phases of this  
illness, cultures may be positive in 20% to 35% of patients with 
  
 
 
pneumonia
24
. The good evidence of streptococcus pneumonia are 
presence of lancet shaped diplococcic and neutrophils containing the 
typical gram positive organisms.  False positive results may be  often 
obtained by this kind of  method since  S. pneumoniae is an endogenous 
flora. At every possible time antibiotic sensitivity must be checked
25
. 
  
Haemophilus influenza  
CAP caused by both encapsulated and un-encapsulated forms of 
haemophilus influenza. In Adults infections like as, cystic fibrosis, 
chronic bronchitis and bronchiectasis are at high risk to get developed. 
Acute exacerbation of COPD is caused by H.influnzae. 
The encapsulated form can cause a life-threatening condition of 
pneumonia in children, followed by a respiratory viral infection. In 
children suppurative meningitis and epiglottitis  are caused by 
H.influnzae, but significantly reduced due to vaccination in infants. 
 
Staphylococcus aureus  
Nosocomial pneumonia is mainly caused by S.aureus . S. aureus is 
an most important cause of secondary bacterial pneumonia after viral 
respiratory illnesses,  in healthy adults and children, for example 
influenza in both adults and children and  measles in children. In  
intravenous drug abuse individuals Staphylococcal pneumonia  
  
 
 
association staphylococcal endocarditis on the right side.  Staphylococcal 
pneumonia is associated with complications like empyema and lung 
abscess
26
 .  
 
Moraxella catarrhalis  
Along  with  H. influenza andS. pneumonia, otitis media is caused 
by M. catarrhalis in children. In adults, M. catarrhalis is the second 
common bacterial cause of COPD acute exacerbation. In the elderly, 
cause of bacterial pneumonia is recognized as M.catarrhalis.  
 
Klebsiella pneumonia  
Gram negative bacterial pneumonia is most frequently caused by 
K. pneumoniae. It frequently afflicts malnourished and debilitated 
persons, particularly with chronic alcoholic person. It is character by 
Thick and gelatin like sputum, and so the organism secretes lots of viscid 
capsular polysaccharides, in which the person may feel difficulty in 
coughing up. 
 
Legionella pneumophila  
In upper respiratory tract,  without pneumonic symptoms, self 
limiting infection caused by L. pneumophila is Pontiac fever. It is the 
causative agent of legionnaire disease, which is a namesake for the 
  
 
 
sporadic and epidemic forms of pneumonia caused by L.pneumophilia. In 
persons with predisposing condition such as renal, cardiac,  hematologic 
or immunologic disease Legionella pneumonia is common. It flourishes 
in the artificial water environments, such as domestic water supply tubing 
system and water cooling towers . Aspiration of contaminated water or 
inhalation of aerosol organisms are thought to be the mode of 
transmission. 
Legionella pneumonia may require frequent hospitalization , may 
be severe and fatality rate  for immune suppressed individuals may vary 
from 30% to 50%. More susceptible person for this organism are Organ 
transplant recipients.    In sputum presence of positive fluorescent 
antibody and in Urine Legionella antigen demonstration  are the Rapid 
diagnosis methods for Legionella pneumonia. Moreover the gold standard 
of diagnosis of Legionella pneumonia is Culture. 
 
Pseudomonas aeruginosa 
P. aeruginosa is seen most commonly in nosocomial pneumonia. 
Due to association with cystic fibrosis infection we discuss this organism  
with community acquired pathogens. In condition such as mechanical 
ventilated patients, neutropenic persons, extensive burn patients and  
patients who are secondary to chemotherapy, Pseudomonas pneumonia is 
  
 
 
more common.  P.aeruginosa spreads extrapulmonarly and in infection 
sites it invades blood vessels. 
  On Histopathological examination, it shows coagulation necrosis 
of lung parenchyma with the necrotic blood vessel walls invaded by 
organism, which is defined as Pseudomonas vasculitis. Since death often 
occurs in few days of infection, Pseudomonas always described as a 
fulminant disease. 
 
Clinical features  
CAP generally presents in two forms as typical and atypical
27
. 
Typical form  
Streptococcal pneumonia is most common pathogen causing 
typical form of CAP. Though sometime anaerobic and aerobic flora of 
oral cavity and H. influenza may also cause typical infection. The typical 
pneumonia is characterized by the sudden onset of fever, with or without 
chills, shortness of the breath,  productive cough  with purulent sputum, 
haemoptysis, pleuritic chestpain, Tachypnoea, tachycardia  and dullness 
as signs of pulmonary consolidation , rales and bronchial breath sounds 
may expressed on physical examination. 
 
 
 
  
 
 
Atypical Form : 
        Atypical pneumonia is mainly caused by M. pneumoniae, but it also 
can caused by Pneumocystis carinii  oral anaerobes, and  Chlamydia 
pneumoniae
28
. Unlike typical form, it is characterized by fever which is 
gradual in onset, shortness of breath and dry cough. Some extra 
pulmonary symptoms like myalgia, headache, fatigue, nausea, vomiting, 
sore throat and diarrhea are also characterized in atypical pneumonia. On 
chest x-ray there are only minimal sign changes compared to typical 
form. 
CAP may sometimes expresses Non respiratory symptoms in lower 
lobe pneumonia, which may expresses as  rigidity, abdominal pain and 
ileus. In severe forms patients may present with symptoms like marked 
confusion, and also present as cerebellar dysfunction, meningitis, 
metabolic disturbances and evidence of hypoxia
29
. Patients who are 
severely ill may some times present with septic shock and with the 
evidence of organ failure. 
We cannot rule out or confirm the pneumonia just only by the 
information obtained from patient as history or by our physical 
examination with the adequate accuracy. 
 
 
 
  
 
 
Diagnosis  
The physician by asking the patient about his living circumstances, 
his occupation, history of travel, contact history with patients and 
exposure to animal history, may get clue about microbial etiology of the 
infection. the clinical and radiological methods may helps in concluding 
the diagnosis of pneumonia. And the laboratory infection will aid us to 
conclude the etiology of the infection
30
. 
 
Clinical Diagnosis  
        Infectious diseases and noninfectious diseases such as chronic 
bronchitis - acute exacerbations, acute bronchitis, radiation pneumonitis, 
pulmonary embolism and  heart failure are the differential diagnosis of 
CAP. Very careful history collecting of a patients is more important. For 
example worsening pulmonary edema suggested by known cardiac 
disease, Secondaries to irradiation therapy suggested by underlying 
carcinoma
31
. Epidemiologic clues, like patients  recent travel history to 
known endemic areas, for example travel to south east Asia, may give 
alert to physician to reach the specific possibilities.  
Moreover, the specificity and sensitivity of the physical 
examination findings are really very  less as an averaging sensitivity of 
58% and specificity of 67%. 
  
 
 
Radiological Diagnosis  
          Since there is very less sensitivity and specificity in physical 
findings is really necessary to differentiate CAP from the other conditions 
by using chest radiograph
32
. Sometimes etiological diagnosis can be 
suggested by radiological results, like tuberculosis is suggested by 
cavitations in the upper lobe and Staphylococcus aureus infection 
suggested by pneumatoceles. In outpatients, treatment for CAP is done 
with the help of clinical and the radiologic assessments, because most of 
the time laboratory results are unavailable to start initial treatment. 
 In some cases, the availability of rapid diagnosis and treatment is 
very important such as, for influenza virus infection, rapid diagnosis is 
very important to start anti-influenza treatment and for the secondary 
prevention of infection
33
. Usually CT is not necessary, but sometimes in a 
patient with foreign body or tumor causing post obstructive pneumonia, it 
is more useful to diagnose
34
. 
  
 
 
 
 
  
 
 
Etiological Diagnosis  
Only by clinical presentation it is difficult to determine the etiology 
of infection. Instead, support of laboratory results is more useful for the 
physician to diagnose. For patients in the intensive care unit, there is no 
data to prove the efficacy between treatment for a specific pathogen and 
empirical therapy. This leads to the questioning of microbial etiology 
establishment, mainly about cost effectiveness of diagnostic testing. 
Moreover, there are number of reasons that can leads to attempt an 
etiologic diagnosis. Narrowing of the beginning empirical therapy is done 
by unexpected pathogen identification,  that reduces the risk of resistance 
and also helps incorrect antibiotic selection
35
. Appropriate empirical 
therapy and resistance to antibiotics are difficult to finalize without 
susceptibility data and culture. 
Blood Culture  
The blood culture results gives very less useful information in spite 
of blood samples collected before the starting of antibiotic theraphy
36
. 
Blood culture report of hospitalized CAP patients are positive only 
approximately 5–14%, and S. pneumonia is isolated organism most 
frequently  because of lack of significant outcome and of low yield values 
  
 
 
blood culture is no more considered as investigation for patient infected 
with CAP.  
Because of all empirical treatment which we use covers 
pneumococcus, blood cultured patients gets positive results. However, 
susceptibility data may allow narrowing of antibiotic therapy in 
appropriate cases. Patients of  high risk criteria such as asplenia, 
neutropenia secondary to pneumonia, chronic liver disease or severe CAP 
or complement deficiencies blood culture should be done. 
Polymerase chain Reaction  
Polymerase chain reaction test is useful for micro organisms like 
mycobacteria and L. pneumophilus.  Amplification of DNA and RNA of 
microorganisms done by Polymerase chain reaction tests. Sometimes 
there is a special test called multiplex PCR which helps in  detection of 
the nucleic acid of C.pneumoniae, M.pneumoniae, and Legionella spp
37
. 
However, for research study purposes  the PCR assays is limited. 
Also it helps us to identify the patients who needs intensive care unit 
admission. In pneumococcal pneumonia patients, by PCR, documentation 
of an increased bacterial load is associated with an increased risk of 
patient need for mechanical ventilation, septic shock and death.  
 
  
 
 
Gram staining and sputum culture  
The sputum Gram's stain is used to assure ensure that a sample 
which collected is suitable for culture. However, certain pathogens are 
identified by their characteristic appearance, by Gram's stain like   S. 
aureus, S. pneumonia and gram-negative bacteria. Sputum sample said to 
be adequate for culture, only if it contains squamous epithelial cells <10 
and >25 neutrophils  per low power field. The Gram's stain and cultures  
specificity and sensitivity  are highly variable. For example in a 
confirmed bacteremic pneumonia, sputum samples cultures  is positive 
only about 50%. 
The etiologies of milder and severe form of CAP are somewhat 
different, so there is a greatest benefit in the staining and culturing  
collected respiratory secretions.  Physician should be careful with 
resistant pathogens and/or unsuspected pathogens and to start with correct 
modification of therapy. Sometimes specific stains for specific microbes 
may be very useful 
Many patients would have started antibiotic treatment and in some 
elderly patients are not able to produce enough amount of sputum for 
staining and culture, This may interfere in the staining and culture 
procedures. Because of dehydration the amount of sputum secreted is 
  
 
 
very less and when we try to correct the dehydration, there is increase in 
the production of sputum and it get infiltrate in lungs, which shows 
infiltrative signs in chest x rays.  
Bronchoalveolar lavage and deep suction aspirate sample collected 
from patients who are  intubated and admitted in ICU when microbiology 
examination done immediately has a very high yield on culture. 
 
Fig : Gram Positive diplococci in sputum gram stain. S.pneumonia 
shown in arrows. 
 
 
 
  
 
 
Serological Examination  
Between convalescent phase and acute phase serum samples, 
diagnostics of infection is generally considered by a titer rise of fourfold 
rise in specific IgM antibody. In the olden days, atypical pathogen 
identification and also selected unusual causative organisms such as 
Coxiella burnetii is done by serologic tests. But now a days, however not 
commonly used because of the time taken to produce the convalescent 
phase samples final result. 
Testing the Antigens  
In urine there are Two antigenic tests available to detect certain 
Legionella and pneumococcal antigens. The sero group 1 detected by this 
test used for community acquired Legionnaires disease. The urine antigen 
test for pneumococcal is also quite specific and sensitive  about >90% 
and 80% respectively. The specificity and sensitivity of the urine antigen 
test for Legionella are as very high as 99% and 90%, respectively. 
Even after the beginning of antibiotic therapy, antigens can be 
detected by both tests. The test is mostly reliable, though false-positive 
results obtained with samples collected from children colonized by 
pneumococcus. Some other test has poor sensitivity like rapid and the 
  
 
 
direct fluorescent antibody tests for respiratory syncytial virus  and 
influenza virus. 
Management  
            Assessment of the severity of the disease is done by several 
criteria. Due to better prognostic correlation and its simplicity, CURB 65 
is most commonly and most often used. Several assessment of pneumonia 
severity are explained as follows
38
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CRB 65  
• Confusion state of patient 
• Respiratory rate of patient more than or equal to 30/min 
• Low blood pressure, that is systolic blood pressure less than 
or equal to 90mmHg or Diastolic Blood Pressure  less than 
or equal to 60mmHg. 
• Age of patient more than or equal to 65. 
 
CURB 65  
•  Confusion state of patient 
• Urea level more than or equal to 7 mmol/lit 
• Respiratory rate of patient more than or equal to 30/min 
  
 
 
• Low blood pressure, that is systolic blood pressure less than 
or equal to 90mmHg or Diastolic Blood Pressure  less than 
or equal to 60mmHg
39
.   
• Age of patient more than or equal to 65 
 
SMRT CO  
• Low systolic blood pressure less than  90mmHg 
• Multi lobar involvement in chest X ray 
• Respiratory rate of patient more than or equal to 25/min 
• Tachycardia, Pulse more than or equal to 125/min 
• Confusion state 
• Poor oxygenation, Spo2 less than 93%, Pao2 less than 
70mmHg. 
 
SMART COP  
• Low systolic blood pressure less than  90mmHg 
• Multi lobar involvement in chest X ray 
• Low albumin level about less than 3.5g/dl 
• Respiratory rate of patient more than or equal to 25/min 
• Tachycardia, Pulse more than or equal to 125/min 
• Confusion state 
  
 
 
• Poor oxygenation, Spo2 less than 93%, Pao2 less than 
70mmHg. 
• Low pH, less than 7.35. 
 
ATS IDSA:  Minor criteria 
• Pao2/Fio2 ratio less than or equal to 250 
• Respiratory rate of patient more than or equal to 30/min 
• Disorientation/ confusion 
• Infiltrates in multi lobes 
• WBC count less than 4000 cells per micro-litre 
• BUN level more than 20mg/dl 
• Core temperature less than 36 degree celcius 
• Platelet count less than 100,000 cells per cubic millimeter. 
 
Major criteria  
•  Vasopressor needed septic shock 
• Mechanical ventilator – invasive. 
 
 
 
 
  
 
 
Pneumonia Severity Index: 
              Pneumonia severity Index used in the prediction of mortality of 
pneumonia. These index are used only in the initial stage of the severity 
of pneumonia because it has its own inherent problem and has non-
absolute parameters
40
.  
                 In  PSI method, there are 20 variables in which points are 
given for each, such as coexisting illness, age, abnormal laboratory  and 
physical  findings. Patients are assigned on different classes with  
mortality rates on basis of scores obtained by this method. Some Clinical 
trials shows that routine use of  PSI results obtained, reduces the rate of 
hospital administration in early stages of the disease.  
         PSI alone cannot be used to decide whether patient needed ICU care 
or not. To conclude that, other data also should be used along with PSI. 
Since PSI needed to taken in account about 20 parameters, which is very 
difficult to apply during emergency situations, there comes other method 
which is very easy to apply, that is CURB 65.  But neither of criteria used 
for the decision taking purpose whether the patient needed ICU or not. 
Best method for this purpose is used by the severity criteria of patients 
given by the American Thoracic Society and the Infectious Diseases 
Society of America. 
  
 
 
Admission of patient in ICU should fulfill at least one of the 
following criteria: 
1. Respiratory frequency more than 30 beats per minute. 
2. Severe respiratory failure 
3. Patient when needs mechanical ventilation 
4. Pao2/Fio2 less than 250 mmHg, if it is Chronic obstructive 
Pulmonary disease it should be less than 200 mmHg. 
5. Severe instability in haemodynamics. 
• Vaso active drugs needed for more than 4 hours 
• Diastolic blood pressure less than 60 mmHg or systolic 
blood pressure less than 90 mmHg. 
• In the hypovolaemic absence urine output less than 20 
ml/hr. 
6. Other severe organ failures. 
7. Spread of pneumonia in radiological feature, that is within 48 hours 
of admission opacity size increase by 50% or get greater. 
8. Haematologic or Metabolic criteria : 
•  Dialysis required due to acute renal failure. 
• Severe acidosis of pH less than 7.30 
• Severe DIC. 
  
 
 
The following things are should be in mind before starting a patient 
with empirical treatment : 
• Compliance, cost of drug and safety 
• Pharmacodynamics and pharmacodynamics of antibiotics 
• Recently administered drugs 
• Local susceptible pattern Knowledge. 
• Most common Pathogen. 
Resistance to Antibiotics  
Now a days Antibiotics are mostly misused in several ways that 
leads to resistance to several antibiotics. Resistance to antibiotics is really 
a major problem that interferes quality of the treatment. Currently, for 
CAP,CA-MRSA and S. pneumoniae has major issue of resistance
41
. 
CA MRSA : 
Recently identified, Phenotypically and genotypically distinct 
strains of CAP and strains that are acquired from hospitals causes  CA 
MRSA
42
. Most infections of later strains are acquired may be directly or 
indirectly by contacting the environment of health care profession and 
now it is called  as HCAP
43
. In recent days, in hospitals, strains acquired 
from hospitals are displace by  strains of CA-MRSA , which hints  the 
increasing in strength of newer strains. 
 
  
 
 
S.pneumonia  
Generally, resistance to pneumococcal infection acquired by  
1. Natural Transformation Process 
2.  By remodeling and  DNA incorporation 
3.  Certain gene mutation. 
Beta lactam drug resistance is mainly due to penicillin binding  
proteins affinity is low. Risk factors of  pneumococcal penicillin-resistant 
infection include an age of  >65 years or <2 years, recently used  
antimicrobial therapy, HIV infection, recent hospitalization, and day care 
hospital  attendance
44
. 
Like  penicillin resistance, macrolides resistance  is increasing by 
several mechanisms. In Europe macrolide resistance  is very high and  
more common, Some times Pneumococcal  infection shows resistance to 
other antibiotics like fluoroquinolones reported
45
.  
Resistant to drugs of more than three antimicrobial with 
mechanism of the action also different  are considered as MDR. The 
antibiotic used in last 3 months is very important risk factor for 
pneumococcal antibiotic-resistant infection. Hence, a patient's prior 
antibiotic  history in treatment plays critical role in avoiding  use of the 
inappropriate antibiotics
46
. 
  
 
 
Table : Antibiotic Treatment of CAP
 
 
 
 
  
 
 
Complications 
       Complications of CAP are divided as Local and general 
complications. Which are listed below
47
, 
 
General complications: 
• Meningitis, 
• Septic arthritis 
• Skin rashes 
• Peritonitis 
• Thrombocytopenia 
• Haemolytic anaemia 
• Gastroenteritis. 
• Failure in circulation like myocarditis and pericarditis 
Local Complications: 
• Respiratory failure 
• Pneumothorax 
• Delayed resolution of lung parenchyma 
• Empyema 
• Lung abscess 
• Pleural effusion 
• Spread to other lobes. 
  
 
 
Like all other infections in severe conditions, CAP also has 
complications that include multi organ failure, shock, Respiratory failure, 
comorbid illnesses exacerbation and coagulopathy . Most important 
complication of CAP  are pleural effusion, lung abscess and metastatic 
infection. Lung abscess sometimes  occur with aspiration or  with CA-
MRSA, S. pneumonia or with P. aeruginosa
48
. 
  Unusual complication like Metastatic infection  needs physician  
attention  immediately where proper workout and treatment is necessary. 
For therapeutic and diagnostic purposes  Pleural effusion must be tapped 
and drained
49
. Aspiration pneumonia is a infection of  mixed 
polymicrobes  that involves  both anaerobes and aerobes. In both 
conditions, drainage must be done, and suspected pathogen covering 
antibiotics should be given. 
 
Prevention  
 The Vaccination is very important preventive method. As  
recommended by ACIP   pneumococcal and  influenza vaccines must be 
followed
50
. Even patients not having obstructive lung diseases, due to  
pneumococcal infection risk, smokers must be strictly warned for 
sessation of smoking. 
  
 
 
In the outbreak of influenza, patients who are not protected and capable 
of getting complications must be vaccinated immediately  and 
chemoprophylaxis should be given with zanamivir  or oseltamivir  for 
duration of  2 weeks till antibody induced by vaccine, reaches high
51
. 
         Immunological memory of long term is given by 7 valent 
conjugated pneumococcal vaccine which is available now a days.  This 
vaccine given to children produces  decrease in the pneumococci of 
antimicrobial resistant type. Also in adults and children it decreases 
pneumococcal disease incidence. However, following the vaccination, 
non vaccine serotypes are used to replace vaccine serotypes for 
subsequent period. 
 
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS AND METHODS 
 
SOURCE OF STUDY: 
Data consists of primary data collected by the principal investigator 
directly from the patients who are admitted in the Government 
Coimbatore  Medical College and Hospital. 
 
DESIGN OF STUDY :  Cross sectional study 
 
PERIOD OF STUDY :  One year, 2016- 2017. 
 
SAMPLE SIZE  :  50 
• 50 patients with Community acquired pneumonia. 
 
INCLUSION CRITERIA: 
• Patients with age > than 12 years  
• Patients having clinical features like fever ( temperature > 
37.8degree celcius) , cough ( less than 4 weeks), production 
of purulent sputum, chest pain, breathlessness. 
• Radiological evidence of pneumonia. 
 
  
 
 
EXCLUSION CRITERIA 
Patients having hospital acquired pneumonia, HIV positive 
patients, tuberculosis, immune compromised, aspiration pneumonia, 
pulmonary infarction. 
METHODOLOGY  
The study is will be undertaken on the patients attending medicine 
out patient department and admitted in the Coimbatore Medical College 
and Hospital, Coimbatore during the study period ( 2016 to 2017). A total 
of 50 patients with Community acquired pneumonia are included in the 
study based on the inclusion/exclusion criteria.  
The list of the patients enrolled in the study is appended along with 
the dissertation. The study excludes minors, pregnant women, mentally-
ill and non-volunteering patients. 
The study is proposed to be conducted after obtaining informed 
signed consent from the patients.  The duration of the study is one year 
from 2016 to 2017.  The principal investigator, after obtaining informed 
signed consent from the patients to participate in the study, collects their 
baseline characteristic details and physical examination details to identify 
Community acquired pneumonia. 
 
 
  
 
 
INVESTIGATIONS : 
• Complete Haemogram 
• Sputum culture and sensitivity 
• Blood culture 
• Chest x-ray posterior-anterior view 
• CT chest 
• Renal function test 
• Liver function test    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
RESULTS 
AGE DISTRIBUTION 
 
Table 1: Age Distribution in decades, in the Study Population 
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE 
< 40 10 20% 
41-50 9 18% 
51-60 16 32% 
> 60 15 30% 
 
 
 
Chart 1 : Age Distribution in decades, in the Study Population 
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Table 2- Age Distribution in the Study Population 
 
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE 
MORE THAN 50 31 62% 
LESS THAN 50 19 38% 
 
 
 
 
Chart 2 – Age Distribution in the Study Population 
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Table 3 – Sex Distribution in the Study Population 
SEX NO OF PATIENTS PERCENTAGE 
MALE 37 74% 
FEMALE 13 26% 
 
 
 
 
 
Chart 3 –  : Sex Distribution in the Study Population 
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Table 4 : Age Vs Sex 
 
 
SEX 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
MALE 24 13 
FEMALE 7 6 
P VALUE - 0.481 
NON SIGNIFICANT 
 
 
 
Chart 4 : Age Vs Sex 
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Table 5 : Cough Manifestation in The Study Population 
 
COUGH NO OF PATIENTS PERCENTAGE 
PRESENT 50 100% 
ABSENT 0 0% 
 
 
 
 
Chart 5 : Cough Manifestation in The Study Population 
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Table 6 : Cough Vs Age 
 
COUGH 
 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 31 19 
ABSENT 0 0 
P VALUE – NIL 
 
 
 
 
Chart 6 : Cough Vs Age 
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Table 7 : Fever Manifestation in the Study Population 
 
FEVER NO OF PATIENTS PERCENTAGE 
PRESENT 49 98% 
ABSENT 1 2% 
 
 
 
 
 
 
Chart 7 : Fever Manifestation in the Study Population 
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Table 8 : Age Vs Fever 
 
FEVER 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 31 18 
ABSENT 0 1 
P VALUE - 0.197 
NON SIGNIFICANT 
 
 
 
 
Chart 8 : Age Vs Fever 
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Table 9 : Expectoration in the Study Population 
 
 
EXPECTORATION NO OF PATIENTS PERCENTAGE 
PRESENT 49 98% 
ABSENT 1 2% 
 
 
 
 
 
Chart 9 : Expectoration in the Study Population 
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Table 10 : Age Vs Expectoration 
 
 
EXPECTORATION 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 30 19 
ABSENT 1 0 
P VALUE - 0.429 
NON SIGNIFICANT 
 
 
 
 
Chart 10 : Age Vs Expectoration 
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Table 11 : Pleuritic Chest in the Study Population 
 
PLEURITIC CHEST NO OF PATIENTS PERCENTAGE 
PRESENT 43 86% 
ABSENT 7 14% 
 
 
 
 
 
Chart11 : Pleuritic Chest in the Study Population 
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Table 12 : Age Vs Pleuritic Chest Pain 
 
 
PLEURITIC CHEST 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 29 14 
ABSENT 2 5 
P VALUE - 0.049 
SIGNIFICANT 
 
 
 
 
Chart 12 : Age Vs Pleuritic Chest Pain 
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Table 13 : Dyspnoea in the Study Population 
 
DYSPNOEA NO OF PATIENTS PERCENTAGE 
PRESENT 43 86% 
ABSENT 7 14% 
 
 
 
 
 
Chart13 : Dyspnoea in the Study Population 
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Table 14 : Age Vs Dyspnoea 
 
 
DYSPNOEA 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 29 14 
ABSENT 2 5 
P VALUE - 0.049 
SIGNIFICANT 
 
 
 
 
Chart 14 : Age Vs Dyspnoea 
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Table 15 : Hemoptysis in the Study Population 
 
HEMOPTYSIS NO OF PATIENTS PERCENTAGE 
PRESENT 8 16% 
ABSENT 42 84% 
 
 
 
 
 
 
Chart15 : Hemoptysis in the Study Population 
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Table 16: Age Vs Hemoptysis 
 
 
HEMOPTYSIS 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 7 1 
ABSENT 24 18 
P VALUE - 0.105 
NON SIGNIFICANT 
 
 
 
Chart 16 : Age Vs Hemoptysis 
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Table 17  : Crepitation in the Study Population 
 
CREPITATION NO OF PATIENTS PERCENTAGE 
PRESENT 49 98% 
ABSENT 1 2% 
 
 
 
 
 
 
Chart17 : Crepitation in the Study Population 
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Table 18 : Age Vs Crepitation 
 
 
CREPITATION 
AGE DISTRIBUTION 
MORE THAN 50 LESS THAN 50 
PRESENT 31 18 
ABSENT 0 1 
P VALUE - 0.197 
NON SIGNIFICANT 
 
 
 
 
Chart 18 : Age Vs Crepitation 
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Table 19 : Cyanosis in the Study Population 
 
CYANOSIS NO OF PATIENTS PERCENTAGE 
PRESENT 8 16% 
ABSENT 42 84% 
 
 
 
 
 
Chart19 : Cyanosis in the Study Population 
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Table 20 : Age Vs Cyanosis 
  AGE DISTRIBUTION 
CYANOSIS MORE THAN 50 LESS THAN 50 
PRESENT 8 0 
ABSENT 23 19 
      
P VALUE - 0.016 
SIGNIFICANT 
 
 
 
 
Chart 20 : Age Vs Cyanosis 
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Table 21 : Bronchial Breath Sounds in the Study Population 
 
BRONCHIAL BREATH  
SOUNDS 
NO OF PATIENTS PERCENTAGE 
PRESENT 48 96% 
ABSENT 2 4% 
 
 
 
 
 
Chart21 : Bronchial Breath Sounds in the Study Population 
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Table 22 : Age Vs Bronchial Breath Sounds 
 
  AGE DISTRIBUTION 
BRONCHIAL BREATH SOUNDS MORE THAN 50 LESS THAN 50 
PRESENT 30 18 
ABSENT 1 1 
      
P VALUE - 0.721 
NON SIGNIFICANT 
 
 
 
 
Chart22 : Age Vs Bronchial Breath Sounds 
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Table 23 : Altered Sensorium in the Study Population 
 
ALTERED SENSORIUM NO OF PATIENTS PERCENTAGE 
PRESENT 3 6% 
ABSENT 47 94% 
 
 
 
 
 
 
Chart23 : Altered Sensorium in the Study Population 
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Table 24 : Age Vs Altered Sensorium 
 
 
AGE DISTRIBUTION 
ALTERED SENSORIUM MORE THAN 50 LESS THAN 50 
PRESENT 3 0 
ABSENT 28 19 
      
P VALUE - 0.162 
NON SIGNIFICANT 
 
 
 
 
 
Chart24 : Age Vs Altered Sensorium 
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Table 25 : Pleural Effusion in the Study Population 
 
PLEURAL EFFUSION NO OF PATIENTS PERCENTAGE 
PRESENT 3 6% 
ABSENT 47 94% 
 
 
 
 
 
Chart25 : Pleural Effusion in the Study Population 
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Table 26 : Age Vs Pleural Effusion 
 
  AGE DISTRIBUTION 
PLEURAL EFFUSION MORE THAN 50 LESS THAN 50 
PRESENT 3 0 
ABSENT 28 19 
      
P VALUE - 0.162 
NON SIGNIFICANT 
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Table 27 : Smokers in the Study Population 
 
SMOKING NO OF PATIENTS PERCENTAGE 
PRESENT 28 56% 
ABSENT 22 44% 
 
 
 
 
 
Chart27 : Smokers in the Study Population 
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Table 28 : Age Vs Smokers 
 
  AGE DISTRIBUTION 
SMOKING MORE THAN 50 LESS THAN 50 
PRESENT 21 7 
ABSENT 10 12 
      
P VALUE - 0.033 
SIGNIFICANT 
 
 
 
 
Chart 28 : Age Vs Smokers 
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Table 29 : Alcoholics in the Study Population 
 
ALCOHOLIC NO OF PATIENTS PERCENTAGE 
YES 22 44% 
NO 28 56% 
 
 
 
 
Chart29 : Alcoholics in the Study Population 
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Table 30 : Age Vs Alcoholics 
 
  AGE DISTRIBUTION 
ALCOHOLIC MORE THAN 50 LESS THAN 50 
YES 18 4 
NO 13 15 
      
P VALUE - 0.010 
SIGNIFICANT 
 
 
 
 
Chart 30 : Age Vs Alcoholics 
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Table 31 : Diabetes Mellitus Patients in the Study Population 
 
DIABETES MELLITUS NO OF PATIENTS PERCENTAGE 
PRESENT 21 42% 
ABSENT 29 58% 
 
 
 
 
Chart31 : Diabetes Mellitus Patients in the Study Population 
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Table 32 : Age Vs Diabetes Mellitus 
 
 
AGE DISTRIBUTION 
DIABETES MELLITUS MORE THAN 50 LESS THAN 50 
PRESENT 19 2 
ABSENT 12 17 
      
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
 
Chart 32 : Age Vs Diabetes Mellitus 
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Table 33 : Hypertension Patients in the Study Population 
 
HYPERTENSION NO OF PATIENTS PERCENTAGE 
PRESENT 18 36% 
ABSENT 32 64% 
 
 
 
 
Chart33 : Hypertension Patients in the Study Population 
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Table 34 : Age Vs Hypertension 
 
  AGE DISTRIBUTION 
HYPERTENSION MORE THAN 50 LESS THAN 50 
PRESENT 17 1 
ABSENT 14 18 
      
P VALUE - 0.481 
NON SIGNIFICANT 
 
 
 
 
 
Chart 34 : Age Vs Hypertension 
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Table 35 : COPD Patients in the Study Population 
 
COPD NO OF PATIENTS PERCENTAGE 
PRESENT 25 50% 
ABSENT 25 50% 
 
 
 
 
Chart35 : COPD Patients in the Study Population 
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Table 36 : Age Vs COPD 
 
 
AGE DISTRIBUTION 
COPD MORE THAN 50 LESS THAN 50 
PRESENT 22 3 
ABSENT 9 16 
      
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
 
Chart 36 : Age Vs COPD 
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Table 37 : Sputum Culture results in the Study Population 
 
SPUTUM CULTURE NO OF PATIENTS PERCENTAGE 
GRAM +VE 44 88% 
GRAM–VE 6 12% 
 
 
 
 
 
Chart37 : Sputum Culture results in the Study Population 
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Table 38 : Gram Staining results in the Study Population 
 
GRAM STAINING NO OF PATIENTS PERCENTAGE 
GRAM POSITIVE 33 66% 
GRAM NEGATIVE 11 22% 
NOT CLEAR 3 6% 
NO GROWTH 3 6% 
 
 
 
 
 
Chart 38 : Gram Staining results in the Study Population 
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Table 39 : Age Vs Gram Staining 
 
AGE DISTRIBUTION 
GRAM STAINING MORE THAN 50 LESS THAN 50 
GRAM POSITIVE 20 13 
GRAM NEGATIVE 9 2 
NOT CLEAR 1 2 
NO GROWTH 1 2 
      
P VALUE - 0.138 
NON SIGNIFICANT 
 
 
 
 
Chart 39 : Age Vs Gram Staining 
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Table 40 : Culture Organisms in the Study Population 
 
CULTURE ORGANISM NO OF PATIENTS PERCENTAGE 
STREPTOCOCCUS 28 56% 
STAOHYLOCOCCUS 5 10% 
KLEBSIELLA 7 14% 
PSEUDOMONAS 4 8% 
ESHCRECHIA COLI 1 2% 
MIXED 2 4% 
NO GROWTH 3 6% 
 
 
 
Chart40 : Culture Organisms in the Study Population 
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Table 41 : Age Vs  Culture Organism 
 
AGE DISTRIBUTION 
CULTURE ORGANISM MORE THAN 50 LESS THAN 50 
STREPTOCOCCUS 16 12 
STAOHYLOCOCCUS 4 1 
KLEBSIELLA 5 2 
PSEUDOMONAS 3 1 
ESHCRECHIA COLI 1 0 
MIXED 1 1 
NO GROWTH 1 2 
      
P VALUE -0.770 
NON SIGNIFICANT 
 
 
 
Chart 41 : Age Vs  Culture Organism 
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Table 42 : Blood Culture Growth Results in the Study Population 
 
BLOOD CULTURE GROWTH NO OF PATIENTS PERCENTAGE 
PRESENT 1 2% 
ABSENT 49 98% 
 
 
 
 
Chart42 : Blood Culture Growth Results in the Study Population 
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Table 43 : Age Vs  Blood Culture Growth 
 
 
AGE DISTRIBUTION 
BLOOD CULTURE GROWTH MORE THAN 50 LESS THAN 50 
PRESENT 1 0 
ABSENT 30 19 
      
P VALUE - 0.429 
NON SIGNIFICANT 
 
 
 
 
Chart 43 : Age Vs  Blood Culture Growth 
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Table 44 : Pleural Fluid Growth Results in the Study Population 
 
PLEURAL FLUID GROWTH NO OF PATIENTS PERCENTAGE 
PRESENT 2 4% 
ABSENT 48 96% 
 
 
 
 
 
Chart44 : Pleural Fluid Growth Results in the Study Population 
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Table 45 : Age Vs  Pleural Fluid Growth 
 
 
AGE DISTRIBUTION 
PLEURAL FLUID GROWTH MORE THAN 50 LESS THAN 50 
PRESENT 2 0 
ABSENT 29 18 
      
P VALUE - 0.258 
NON SIGNIFICANT 
 
 
 
 
Chart 45 : Age Vs  Pleural Fluid Growth 
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Table 46 : Consalidation in X Ray Results in the Study Population 
 
CONSOLIDATION IN X RAY NO OF PATIENTS PERCENTAGE 
BILATERAL 12 24% 
RIGHT LOWER LOBE 16 32% 
RIGHT UPPER LOBE 4 8% 
LEFT LOWER LOBE 12 24% 
LEFT UPPER LOBE 4 8% 
NORMAL 2 4% 
 
 
 
 
Chart 46 : Consolidation in X Ray Results in the Study Population 
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Table  47 : Age Vs  Consolidation in X Ray 
 
  AGE DISTRIBUTION 
CONSOLIDATION IN X RAY MORE THAN 50 LESS THAN 50 
BILATERAL 10 2 
RIGHT LOWER LOBE 8 8 
RIGHT UPPER LOBE 2 2 
LEFT LOWER LOBE 8 4 
LEFT UPPER LOBE 2 2 
NORMAL 1 1 
      
P VALUE - 0.547 
NON SIGNIFICANT 
 
 
 
 
Chart 47 : Age Vs  Consolidation in X Ray 
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CONSOLIDATION IN CT 
CHEST 
NO OF 
PATIENTS 
PERCENTAG
E 
BILATERAL 17 34% 
RIGHT LOWER LOBE 16 32% 
RIGHT UPPER LOBE 4 8% 
LEFT LOWER LOBE 11 22% 
LEFT UPPER LOBE 2 4% 
 
Table 48 : Consolidation in CT Chest Results in the Study Population 
 
 
 
Chart 48 : Consalidation in CT Chest Results in the Study 
Population 
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Table 49 : Age Vs  Consolidation in CT Chest 
 
 
AGE DISTRIBUTION 
CONSOLIDATION IN CT 
CHEST 
MORE THAN 
50 
LESS THAN 
50 
BILATERAL 14 3 
RIGHT LOWER LOBE 8 8 
RIGHT UPPER LOBE 2 2 
LEFT LOWER LOBE 7 4 
LEFT UPPER LOBE 0 2 
      
P VALUE - 0.421 
NON SIGNIFICANT 
 
 
Chart 49 : Age Vs  Consolidation in CT Chest 
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Table 50 : Signs And Symptoms in the Study Population 
SIGNS & SYMPTOMS NO OF PATIENTS PERCENTAGE 
COUGH 50 100% 
FEVER 49 98% 
EXPECTORATION 49 98% 
PLEURITIC PAIN 43 86% 
DYSPNOEA 43 86% 
HEMOPTYSIS 8 16% 
CREPITATION 49 98% 
CYANOSIS 8 16% 
BRONCHIAL BREATH SOUNDS 48 96% 
ALTERED SENSORIUM 3 6% 
PLEURAL EFFUSION 3 6% 
 
 
 
Chart  50 : Signs And Symptoms in the Study Population 
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Table 51 : Co Morbidities in the Study Population 
 
CO MORBIDITIES NO OF PATIENTS PERCENTAGE 
SMOKING 28 56% 
ALCOHOLIC 22 44% 
DIABETES  21 42% 
HYPERTENSION 18 36% 
COPD 25 50% 
 
 
 
 
Chart  51 : Co Morbidities in the Study Population 
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Table 52 : Culture Specimens in the Study Population 
 
CULTURE SPECIMEN NO OF PATIENTS PERCENTAGE 
SPUTUM 47 94% 
BLOOD 1 2% 
 
 
 
 
Chart 52 : Culture Specimens in the Study Population 
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Table 53 : Correlation between Gram Negative Organism and factors 
like smoking and COPD 
 
GRAM NEGATIVE (N=11) 
FACTORS PRESENT ABSENT 
SMOKING 7(63%) 4(37%) 
COPD 7(63%) 4(37%) 
 
 
 
 
 
Chart  53 : Correlation between Gram Negative Organism and 
factors like smoking and COPD 
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Table 54 : Age Vs Duration of Disease 
 
 
DURATION OF DISEASE (DAYS) 
AGE MEAN SD 
MORE THAN 50 8.67 2.15 
LESS THAN 50 6.89 1.1 
      
P VALUE - 0.002 
SIGNIFICANT 
 
 
 
Chart 54 : Mean Duration of Disease 
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Table 55: Disease Outcome in the Study Population 
 
DISEASE OUTCOME NO OF PATIENTS PERCENTAGE 
DIED 3 6% 
DISCHARGED 47 94% 
 
 
 
 
Chart 55: Disease Outcome in the Study Population 
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Table 56 : Age Vs Disease Outcome 
 
 
AGE DISTRIBUTION 
DISEASE OUTCOME MORE THAN 50 LESS THAN 50 
DIED 3 0 
DISCHARGE 28 19 
      
P VALUE - 0.016 
SIGNIFICANT 
 
 
 
Chart 56 : Age Vs Disease Outcome 
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DISCUSSION  
50 Patients with Community Acquired Pneumonia in Coimbatore 
medical college hospital has taken for this study. 
 
Incidence of age and sex : 
< 40 years, totally 10 patients. (20%) 
         41 – 50 years, 9 patients (18%) 
51 – 60 years. 16 patients (32%) 
>60 years, 15 Patients. (30%) 
• In this study 37 patients were male 74% 
13 patients were female 26% More prevalence in male than in female. 
• In this study,  Age groups >50 years   31 patients 
<50 years   19 Patients. 
P value   - 0.481 
Not significant in this study. 
 
Clinical Manifestation:  
• Cough present almost in all patients. So no significant difference in 
age group. 
• Fever present in nearly all patients. Only few patients had absence 
of fever.  
•  
  
 
 
P value – 0.197 
No significant difference in age groups 
• Expectoration  present in nearly all patients 
P value – 0.429. 
No significant difference in age groups 
• Pleuritic chest pain present in 86% of patients. 
P value 0.049 
More Significant in age >50 years.   
• Haemoptysis present in 16% of patients and absent in 84% 
No significant difference in age groups 
• Crepitations present in almost all patients , 98% 
No significant difference in age groups   
• Cyanosis present in 84% of patients, absent in 16% 
P value 0.016 
More Significant in age >50 years 
• Bronchian breath sounds present in almost all patients , 96% 
P value 0.721 
No significant difference in age groups   
• Altered sensorium  present in 6% of patients, absent in 94% 
3 patients aged >50 years had altered sensorium among 28 patients. 
Age <50years had no altered sensorium. 
  
 
 
Over all clinical manifestation: 
• Cough and fever are more common 
• Expectoration, pleuritic chest pain, cripitations, bronchial breath 
sounds, altered sensorium, pleural effusion observed in only few 
patients. 
• Cyanosis and hemoptysis seen in very few number of patients, only 
around 16% 
 
Risk Factors : 
• Smoking observed in 56% of patients with pneumonia. 
Smokers of age more than 50 years had pneumonia 
So smoking is more significant in patients aged >50 years. With p Value 
0.033 
• Smoking with 56% and COPD with 50% are more common  
associated risk factors for pneumonia 
• Alcohol is observed in 44% and absent in 56% of the patients 
Alcohol  is significant in patients aged >50 years. With p Value 
0.010 
• Diabetes Mellitus is observed in 42% and absent in 58% of the 
patients 
  
 
 
Diabetes Mellitus is significant in patients aged >50 years. With p 
Value 0.001 
• Hypertension  present in36% of patients, absent in 64% 
No significant difference in age groups, with p Value 0.481. 
• COPD is observed in 50% and absent in 50% of the patients 
COPD  is significant in patients aged >50 years. With p Value 0.001 
• Sputum Culture : 
        Gram Positive in 66% and Gram negative in 22%, undetermined in 
6% and no growth in 6%. 
No significant difference in age groups, with p Value 0.138. 
• Among Gram Positive, Streptococcal pneumonia is observed in 
56% of the patients. 
• Among gram negative Staphylococcal about 10%, klebsiella 14%, 
Pseudomonas 8%, E.Coli 2%, Mixed 4%, No growth 6%. No 
significant difference in age distribution. 
• Smoking and COPD patients were affected by gram negative 
organisms. 
• Blood Culture Growth : 
        Present in 2% and absent in 98% of the patients. 
 
 
  
 
 
No significant p value in age distribution.  
• Pleural Fluid Growth : 
 Present in 4% and absent in 96% of the patients. 
No significant p value in age distribution.  
• Sputum culture yields 94% and blood culture yields 2% 
• Chest X Ray : 
 Bilateral Consolidation 24% 
 Right lower lobe 32% 
Right upper lobe   8% 
Left lower lobe 24% 
Left upper lobe 8% 
Normal 4% 
No significant p value in age distribution.  
Right lower lobe followed by Left lower lobe and bilateral. 
• CT Chest : 
 Bilateral Consolidation 34% 
Right lower lobe 32% 
Right upper lobe   8% 
Left lower lobe 22% 
Left upper lobe 4% 
No significant p value in age distribution.  
Bilateral followed by Right lower lobe and then Left lower lobe involved 
  
 
 
• Pneumonia in Hospital Stay: 
>50 years – 8.67 days 
<50 years – 6.89 days 
Significant p Value of about 0.002, in age distribution. 
Mean duration of Hospital stay  6 – 8 days. 
• Disease Outcome : 
    Discharged – 94% 
    Died – 6% 
Significant p Value of about 0.016, in age distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
o Males affected more than female 
o Streptococcal pneumonia is the common pathogen causing 
community acquired pneumonia 
o Followed by Klebsiella pneumonia observed in this study. 
o E.coli, Pseudomonas ard staphylococcus observed in few patients. 
o Gram negative organism common in elderly patient, COPD and in 
Smokers. 
o Common age group involved are 40 – 60 years. However old age 
groups mostly affected in pneumonia. 
o Right lung is involved in majority of patients 
o Patients with comorbid conditions like Diabetes Mellitus are 
affected by pneumonia 
o Smoking, COPD and Alcohol are major risk factors 
o Sputum culture yields organism 
o Blood culture yield no organism, In spite of pneumonia, sputum 
culture is negative in some patients. 
o Significant morbidity and mortality in old age groups 
o Our study will use to identify the common organism in CMCH, 
and useful for physicians to start empirical treatment. 
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ANNEXURE-1 
 
PROFORMA 
 
NAME  AGE  
OCCUPATION  SEX  
SOCIO ECONOMIC 
STATUS 
 IP NO  
ADDRESS  
CHIEF COMPLAINTS 
 
 
 PRESENT HISTORY  
1. COUGH 
2. FEVER 
3. EXPECTORATION 
4. DYSPNOEA 
5. PLEURITIC CHEST 
PAIN 
6. HEAMOPTYSIS 
7. ALTERED 
SENSORIUM 
 
 Yes/no                           
 
Duration Other 
features 
PAST HISTORY  
1. SHT 
2. DM 
3. COPD 
4. TB 
5. EPILEPSY/CVA 
6. HIV 
7. CAD 
Duration  Treatment  
PERSONAL HISTORY 
1. ALCOHOL 
CONSUMPTION- 
2. SMOKING  
3. DIET  
4. DRUG INTAKE  
 
Quantity -              Duration  
GENERAL EXAMINATION 
BP 
 
PR  
 
 
CONSCIOUS LEVEL- 
 
PALLOR 
 
  
 
 
SPO2 
 
TEMP 
 
RR 
ICTERUS- 
 
CYANOSIS 
 
DYSPNEA- 
 
PEDAL EDEMA- 
SYSTEM EXAMINATION –    
CVS  
RS  
ABD  
CNS  
BASE LINE 
INVESTIGATIONS- 
 
 
 
 
 
         CBC            RFT         LFT 
SPECIAL BLOOD 
INVESTIGATIONS 
 
 
SPUTUM 
AFB 
SPUTU
M 
GRAM 
STAIN 
SPUTU
M 
CULTU
RE 
BLOOD 
CULTURE 
 
 
 
 
 
 
 
PLEURAL 
FLUID 
CULTURE 
RADIOLOGICAL 
INVESTIGATIONS 
 
 
 
X RAY CHEST     CT CHEST  
FINAL DIAGNOSIS  
TREATMENT  
 
                                                            
 
 
 
 
 
 
  
 
 
ANNEXURE -2 
 
CONSENT FORM 
 
Yourself Mr./Mrs./Ms………………………………..  are being asked to 
be a participant in the research study titled “Clinical, Bacteriological and 
Radiological Study of Community Acquired Pneumonia”in CMC Hospital, 
Coimbatore, conducted by DR.R.REKA M.D., Post Graduate Student, 
Department of General Medicine, Coimbatore Medical College. You are 
eligible after looking into the inclusion criteria. You can ask any question you 
may have before agreeing to participate. 
Research Being Done 
 
Clinical, Bacteriological and Radiological Study of Community 
Acquired Pneumonia 
Purpose of Research 
To study Clinical, Bacteriological and Radiological aspect of 
Community Acquired Pneumonia 
Decline from Participation 
 
You have the option to decline from participation in the study 
existing protocol for your condition. 
Privacy and Confidentiality 
 
Privacy of individuals will be respected and any information about 
you or provided by you during the study will be kept strictly confidential. 
 
 
 
  
 
 
 
Authorization to publish Results   
 
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified.               
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me, and I may ask questions at any time. 
 
-------------------------------                            -------------------------------   
Signature /Left thumb impression                                Date 
(volunteer)   
 
--------------------------------                           -----------------------------
Signature of witness                                                Date 
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                                                                                           ANNEXURE-3 
MASTER CHART 
S
.N
O
 
NAME 
A
/S
 
C
O
U
G
H
 
F
E
V
E
R
 
E
X
P
E
C
T
o
R
A
T
IO
N
 
P
L
E
U
R
IT
IC
 C
H
E
S
T
 P
A
IN
 
D
Y
S
P
N
O
E
A
 
H
E
M
O
P
T
Y
S
IS
 
C
R
E
P
IT
A
T
IO
N
S
 
C
Y
A
N
O
S
IS
 
B
R
O
N
C
H
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L
 B
S
 
A
L
T
E
R
E
D
 S
E
N
S
O
R
IU
M
 
P
L
E
U
R
A
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 E
F
F
U
S
IO
N
 
S
M
O
K
IN
G
 
A
L
C
O
H
O
L
 
D
M
/S
H
T
 
C
O
P
D
 
S
P
U
T
U
M
 G
R
A
M
 S
T
A
IN
 
S
P
U
T
U
M
 C
/S
 
B
L
O
O
D
 C
/S
 
P
L
E
U
R
A
L
 
F
L
U
ID
 
A
N
A
L
Y
S
IS
 
C
O
N
S
O
L
I
D
A
T
IO
N
 
D
U
R
A
T
IO
N
 
OUTCOME C
X
R
 
C
T
 C
H
E
S
T
 
1 RAMAN 20/M P P P P A A P A P A A YES YES NO NO POS STREP NO NO 
RT 
LL 
RTLL 7 DISCHARGED 
2 KARUPPUSAMY 45/M P P P A P A P A P A A YES NO DM NO POS STREP NO NO 
RT 
LL 
RTLL 6 DISCHARGED 
3 KRISHNAN 50/M P P P P P A P A P A A YES NO NO YES POS STREP NO NO B/L B/L 9 DISCHARGED 
4 SAGADEVAN 55/M P P P A A A P A P A A NO YES NO YES POS STREP NO NO 
LT 
LL 
LT 
LL 
6 DISCHARGED 
5 SIVASAMY 60/M P P A P P P P A P A A YES YES 
DM/ 
SHT 
YES NEG KLEB NO NO NO B/L 9 DISCHARGED 
6 KANNAN 46/M P P P P P A P A P A A NO NO NO NO POS STAPH NO NO 
LT 
LL 
LT 
LL 
6 DISCHARGED 
7 ANBARASAN 52/M P P P P P A P A P A A YES YES DM YES NG NG NO NO B/L B/L 8 DISCHARGED 
8 KITTAN 61/M P P P P P A P P P A A YES YES DM YES POS STAPH NO NO 
LT 
LL 
LT 
LL 
9 DISCHARGED 
9 KATHIRAVAN 35/M P P P P A A P A P A A NO NO NO NO POS STREP NO NO 
LT 
LL 
LT 
LL 
8 DISCHARGED 
10 JAYAPAL 56/M P P P P A A P A P A A NO YES SHT NO NEG KLEB NO NO LTUL B/L 8 DISCHARGED 
11 GOPAL 58/M P P P A P A P A P A A YES YES 
DM/ 
SHT 
NO POS STREP NO NO 
RT 
LL 
RTLL 7 DISCHARGED 
12 RAJENDRAN 60/M P P P P P A P A P A A YES NO DM YES POS STREP NO NO 
RT 
LL 
RTLL 8 DISCHARGED 
13 RAJA 62/M P P P P P P P P P P A YES YES 
DM/ 
SHT 
YES NEG PSEUD NO NO B/L B/L 14 DIED 
  
 
 
14 RANGASAMY 40/M P P P P P A P A P A A YES YES NO YES NO MIXED NO NO B/L B/L 6 DISCHARGED 
15 RAMASAMY 58/M P P P P P A P A P A A YES YES NO NO POS STREP NO NO 
RT 
LL 
RTLL 6 DISCHARGED 
16 RANJITH  35/M P P P P P A P A P A A NO NO NO NO POS STREP NO NO LTLL 
LT 
LL 
7 DISCHARGED 
17 RAMESH 32/M P P P P P A P A P A A NO YES NO NO POS STREP NO NO 
RT 
LL 
RTLL 6 DISCHARGED 
18 CHELLAPAN 60/M P P P P P A P A P A A YES NO NO YES NEG KLEB NO NO LTUL B/L 8 DISCHARGED 
19 PALANISAMY 56/M P P P P P P P A P A A YES YES 
DM/ 
SHT 
NO POS STREP NO NO LTLL 
LT 
LL 
6 DISCHARGED 
20 PERUMAL 62/M P P P P P P P P P A A YES YES DM YES NEG ESCHER NO NO B/L B/L 12 DISCHARGED 
21 MUTHUSAMY 60/M P P P P P A P A P A A YES YES SHT YES POS STREP NO NO 
RT 
LL 
RTLL 7 DISCHARGED 
22 MUNUSAMY 58/M P P P P P A P A P A A NO NO 
DM/ 
SHT 
YES POS STREP NO NO 
RT 
LL 
RTLL 7 DISCHARGED 
23 KANNIAPPAN 46/M P P P P P P P A P A A YES YES NO NO POS STREP NO NO LTUL LTUL 7 DISCHARGED 
24 SILAMBARASAN 33/M P P P A P A P A P A A NO NO NO NO NEG KLEB NO NO RTUL RTUL 8 DISCHARGED 
25 MOHAN 62/M P P P P P A P P P A P YES YES 
DM/ 
SHT 
YES NEG PSEUD NO STAPH B/L B/L 10 DISCHARGED 
26 MALAIASAMY 59/M P P P P P A P A P A A YES YES 
DM/ 
SHT 
YES POS STAPH NO NO LTLL LTLL 8 DISCHARGED 
27 DURAISAMY 59/M P P P P P A P A P A A NO NO NO NO POS STREP NO NO RTLL RTLL 7 DISCHARGED 
28 THIRUMALAI 68/M P P P P P A P P P P P YES YES 
DM/ 
SHT 
YES POS STREP NO NG B/L B/L 13 DIED 
29 NEELAMEGAM 63/M P P P P P A P P P A A YES NO SHT YES NEG PSEUD NO NO LTLL B/L 10 DISCHARGED 
30 NATESAN 66/M P P P P P P P A P A A NO NO DM NO NEG KLEB NO NO RTUL RTUL 7 DISCHARGED 
31 NAGARAJ 56/M P P P P P P P A A A A YES YES NO NO POS STREP NO NO B/L B/L 6 DISCHARGED 
32 NANJAPPAN 65/M P P P P P A P A P A A YES YES NO NO POS STREP NO NO LTLL LTLL 8 DISCHARGED 
33 CHIDAMBARA 48/M P P P P P A P A P A A NO NO NO NO POS STREP NO NO RTLL RTLL 6 DISCHARGED 
34 MYILSAMY 38/M P P P P P A P A P A A YES NO NO YES POS STREP NO NO NO RTLL 6 DISCHARGED 
35 MARIMUTHU 63/M P P P P P A P P P A A YES YES DM YES NEG KLEB NO NO B/L B/L 8 DISCHARGED 
36 NALLAKANNU 49/M P P P P P A P A P A A YES NO NO NO NG NG NO NO RTLL RTLL 6 DISCHARGED 
  
 
 
 
 
 
 
 
 
 
 
 
 
37 RANGASAMY 70/M P P P P P P P P P P A YES YES 
DM/ 
SHT 
YES POS STREP NO NO B/L B/L 12 DIED 
38 JOTHI 36/F P P P A A A P A P A A NO NO NO NO POS STREP NO NO RTLL RTLL 8 DISCHARGED 
39 SELVI 43/F P P P A A A P A P A A NO NO DM NO NG NG NO NO RTLL RTLL 6 DISCHARGED 
40 MYLATHAL 62/F P P P P P A P A P A A YES NO 
DM/ 
SHT 
YES POS STAPH STAPH NO B/L B/L 10 DISCHARGED 
41 RAJAMMAL 35/F P P P A P A P A P A A NO NO NO NO POS STREP NO NO LTLL LTLL 8 DISCHARGED 
42 KANNAMMAL 62/F P P P P P A P A P A A NO NO SHT YES POS STREP NO NO LTLL LTLL 8 DISCHARGED 
43 SEETHA 46/F P P P P A A P A P A A NO NO SHT NO POS STREP NO NO RTLL B/L 9 DISCHARGED 
44 LAKSHMI 30/F P A P P P A A A A A A NO NO NO NO NG NG NO NO RTUL RTUL 6 DISCHARGED 
45 PARVATHI 46/F P P P P P A P A P A A NO NO NO NO NEG KLEB NO NO LTUL LTUL 6 DISCHARGED 
46 KARUPATHAL 59/F P P P P P A P A P A A NO NO DM NO POS STREP NO NO RTLL RTLL 7 DISCHARGED 
47 CHELLAMMAL 61/F P P P P P A P A P A A NO NO 
DM/ 
SHT 
YES POS STREP NO NO RTLL RTLL 8 DISCHARGED 
48 RANGAMMAL 62/F P P P P P A P A P A A NO NO 
DM/ 
SHT 
YES POS STAPH NO NO B/L B/L 10 DISCHARGED 
49 RAJAMANI 70/F P P P P P A P A P A P YES NO NO YES POS STREP NO STREP RTUL RTUL 12 DISCHARGED 
50 RAJAMMAL 60/F P P P P P A P A P A A NO NO SHT YES NO MIXED NO NO LTLL LTLL 10 DISCHARGED 
  
 
 
ABBREVIATIONS FOR MASTER CHART 
 
 
P - PRESENT 
A - ABSENT 
POS - POSITIVE 
NEG - NEGATIVE 
DM - DIABETES MELLITUS 
SHT-SYSTEMIC HYPERTENSION 
RT UL - RIGHT UPPER LOBE 
RT LL - RIGHT LOWER LOBE 
LT UL - LEFT UPPER LOBE 
LT LL - LEFT LOWER LOBE 
B/L - BILATERAL 
C/S - CULTURE AND SENSITIVITY 
CXR - CHEST X RAY 
STREP - STREPTOCOCCUS PNEUMONIAE 
STAPH - STAPH AUREUS 
KLEB - KLEBSIELLA PNEUMONIAE 
PSEUDO - PSEUDOMONAS  AERUGINOSA 
ESCHERIA - ESCHERIA COLI 
NG - NO GROWTH 
 
 
